| Id: | acc4428 |
| Group: | 1sens |
| Protein: | PHLPP2 |
| Gene Symbol: | Phlpp2 |
| Protein Id: | Q8BXA7 |
| Protein Name: | PHLP2_MOUSE |
| PTM: | phosphorylation |
| Site: | Ser1119 |
| Site Sequence: | RPERRCSLHPASSAGVFQRQP |
| Disease Category: | Endocrine and metabolic diseases |
| Disease: | Obese |
| Disease Subtype: | fatty liver |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | glucagon |
| Drug Info: | Glucagon is a hormone that raises blood glucose levels by stimulating the liver to convert glycogen into glucose. It is used to treat severe hypoglycemia. |
| Effect: | modulate |
| Effect Info: | "Glucagon enhances the phosphorylation of PHLPP2 at Ser1119 and Ser1210 through activating PKA. The phosphorylation of PHLPP2 affects its stability, preventing these mice from terminating insulin signaling and ultimately leading to elevated DNL and fatty liver. " |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 28859855 |
| Sentence Index: | 28859855_11 |
| Sentence: | "In HFD-fed C57BL/6J or db/db obese mice, endogenous PHLPP2 was degraded by glucagon and PKA-dependent phosphorylation of PHLPP2 (at Ser1119 and Ser1210), which led to PHLPP2 binding to potassium channel tetramerization domain containing 17 (KCTD17), a substrate-adaptor for Cul3-RING ubiquitin ligases." |
Sequence & Structure:
MKHNGSRTCLNRRSRFGSRERDWLREDVKRGCVYLYGADTTTATTTTSSSSSSSSSSDLHLVLCTVETPASEICAGEGRESLYLQLHGDLVRRLEPSERPLQIVYDYLSRLGFEDPVRIQEEATNPDLSCMIRFYGEKPCQMDHLDRILLSGIYNVRKGKTQLHKWAERLVVLCGTCLIVSSVKDCQTGKMHILPLVGGKIEEVKRRQHSLAFSSAGAQAQTYHVSFETLAEYQRWQRQASKVVSQRMSTVDLSCYSLEEVPEHLFYSQDITYLNLRHNFMQLERPGGLDTLHKFSQLKGLNLSHNKLGLFPVLLCEISTLTELSLSCNGFHDLPSQIGKLLNLQTLSLDGNGLTALPDELGNLRQLTSLGISFNDFRHIPEVLEKLTMLDKVAMAGNRLEVLNLGALTRMSQVKHVDLRMNHLKTVITENMEGNKHITHMDLRDNQLTDLDLSSLCSLEQLHCERNQLRELTLSGFSLRTLYASWNRLTAVNVYPVPSLLTSLELSQNLLECVPDWACEAKKLEILDISHNLLTEVPMRILSSLSLRKLMVGHNHIHVLPALVEHIPLEVLDIQHNTLSRLPDTLFSKALNLRYLNASANSLESLPSACAGEESLSVLQLLYLTSNLLTDQCIPVLVGHPHLRVLHLANNQLQTFPASKLNKLEQLEELNLSGNKLTAIPTTIANCKRLHTLVAHANNISIFPEILQLPQIQFVDLSCNDLTEILIPEALPATLQDLDLTGNTNLVLEHKTLDMFSHITALKIDQKPLPATDSAVTSTFWSHGLAEMAGQRNKLCVSALAMDNFAEGVGAVYGMFDGDRNEELPRLLQCTMADVLLEEVQHSTNDTVFMTNTFLVSHRKLGMAGQKLGSSALLCYIRPDTADPTSSFSLTVANVGMCQAVLCRGGKPVPLSKVFSLEHDPEEAQRVKDQKAIITEDNKVNGVTCCTRLLGCTYLYPWILPKPHIASTPLTIQDELLILGNKALWEHLSYLEAVNAVRHVQDPLAAAKKLCTLAQSYGCQDNVGAMVVYLNIGEEGCTCEMNGLTLPGPVGFASTAALKDTPKPTTPSSSSGIASEFSSEMSTSEVSSEVGSTASDEHNTVGLEASLLPRPERRCSLHPASSAGVFQRQPSCATFSSNQSDNGLDSDDDQPVEGVITNGSRVEVEVDIHCCRGREPESSPPLPKNSSNACSEERARGAGFGIRRQNSVNSGILLPANRDKMELQKSPSTSCLYGKKLSNGSIVPLEDSLNLIEVATEAPKRKTGYFAAPTQLEPEDQFVVPRDLEEEVKEQMKQHQEGRPEPEPRGEERTEPLEEFDTAL
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
